drugset / Trial / NCT01419184

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

NCT01419184

Phase 4 Completed 250 enrolled Merck & Co., Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This was a real-world, prospective, open-label, multicenter study in which participants were randomized (1:1) to receive intravenous (IV) vancomycin or IV daptomycin. The purpose of this study is to compare infection-related hospital length of stay, along with a number of participant-reported outcomes, between participants with complicated skin and soft tissue infection treated with daptomycin and vancomycin.

Timeline

Start
2011-09-09
Primary completion
2012-09-01
Completion
2012-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified 4 mg/kg Intravenous
Comparator Vancomycin Other / unclassified Intravenous